Gilead Sciences is trading lower today, mirroring a broader downturn across the healthcare sector that has seen peers like Regeneron, Amgen, and Vertex also experience notable declines. This downward pressure persists despite the company receiving FDA approval on August 27 for Bixlenvo, a new once-daily HIV treatment regimen. Additionally, the stock is facing technical headwinds following a 13F filing from late August 27, which revealed that Bamco Inc. NY reduced its stake in the company by 40.0% during the second quarter.